NEJM: Actemra Studied in COVID pneumonia and shown to improve outcomes (mech ventilation or death ;12 vs 19.3%) but did not improve survival (10.4 vs 8.6%). 389 hospitalized pts randomized 2:1 to get 2 IV doses Actemra +SOC vs SOC alone https://t.co/BdslXFXOYD